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ABSTRACT
Aim – There is a direct correlation between 25-hydroxyvitamin D (25(OH)D) levels and
insulin sensitivity. Furthermore, women with gestational diabetes (GDM) may have lower
levels of 25(OH)D compared to controls. The present study intended to investigate 25(OH)D
levels and their association with insulin sensitivity and insulin secretion in women with prior
GDM and controls 3.2 years after delivery.
Methods – In total 87 patients with prior GDM and 45 randomly selected controls (age
range: 22-44 years) with normal glucose tolerance during pregnancy nested within a cohort
of all deliveries at Saint Margit Hospital, Budapest between 01/01/2005-31/12/2006 were
examined. 25(OH) D levels were measured by radioimmunoassay. Insulin sensitivity and
fasting insulin secretion were estimated using the HOMA calculator, early insulin secretion
by the insulinogenic index based on a 75g oral glucose tolerance test.
Results – There was no significant difference in 25(OH)D levels between cases and controls
(27.2±13.1 [±SD] vs. 26.9±9.8 ng/l). There was a positive association between HOMA
insulin sensitivity and 25(OH)D levels (β=0.017, 95% CI: 0.001-0.034 / 1 ng/ml) that was 
robust to adjustment for age and BMI. There was a nonsignificant association between
HOMA insulin secretion and 25(OH)D (p=0.099), while no association was found with the
insulinogenic index.
Conclusions – Prior GDM status was not associated with 25(OH)D levels, however 25(OH)
D levels were associated with HOMA insulin sensitivity. It is hypothesized that the
association between HOMA insulin secretion and 25(OH)D levels is related to the
autoregulation of fasting glucose levels as no association between 25(OH)D and
insulinogenic index was found.
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TEXT
Introduction
The role of 25-hydroxyvitamin D (25(OH)D) in calcium and bone metabolism has been
known for decades. Recent evidence suggests more complex involvement of 25-
hydroxyvitamin D in health and disease. Osteopathy and other chronic conditions such as
autoimmune diseases, diabetes, metabolic syndrome, multiple sclerosis and certain
malignancies are associated with low levels of 25-hydroxyvitamin D.[1-5] 25-
hydroxyvitamin D deficiency is rather common, recent studies reported a prevalence of
77% in the United States, 37% in Canada, and 50-70% in European populations.[6, 7]
An association between 25-hydroxyvitamin D levels and insulin sensitivity regardless of
body mass index (BMI)/obesity is suggested by several studies, mostly in populations
with an increased risk of diabetes.[2, 8-11] In a randomized, controlled trial among
subjects with a high risk of diabetes, oral supplementation of vitamin D prevented the
deterioration of insulin sensitivity in the short term.[12] Further, it is suggested that levels
and supplementation of 25(OH)D could have a bidirectional association with adiposity, as
supplementation of vitamin D as well as 25(OH)D levels were inversely associated with
visceral adiposity and adipocyte size in women who underwent abdominal gynaecological
surgery.[13]
An association between vitamin D deficiency and type 2 diabetes is supported by cross-
sectional studies.[8, 14, 15] A similar longitudinal association was found between low
serum 25-hydroxyvitamin D levels and risk of incident of type 2 diabetes.[16] In addition,
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randomized trials demonstrated a direct link between increased vitamin D intake and a
reduced risk of type 2 diabetes.[14, 15, 17]
Although the analogy between gestational diabetes (GDM) and type 2 diabetes is well
accepted and supported by a number of common risk factors, little is known about the
association of serum 25-hydroxyvitamin D levels and the risk of GDM.[18] Cross-
sectionally, some studies have reported lower levels of 25-hydroxyvitamin D among
women with GDM,[19-21] while others have not.[22-24] In a prospective study, lower
first trimester 25(OH)D levels were related incident GDM.[25] It is of note that equivocal
evidence for an association between 25-hydroxyvitamin D levels and insulin sensitivity
during pregnancy was found both in cross-sectional and prospective studies.[22, 23, 25-
27] Furthermore, two experiments (one randomized trial) suggest that vitamin D
supplementation (with rather large dosages) may improve insulin sensitivity in both GDM
and shortly after delivery.[28, 29]
There is limited information available on 25-hydroxyvitamin D levels after delivery.
After delivery (6 weeks-12 months), 25(OH)D levels probably increase compared to
midpregnancy levels, although it appears they may remain lower in women with prior
GDM compared to those who had a non-GDM pregnancy. [30] We hypothesized that (1)
25-hydroxyvitamin D levels would remain lower in prior GDM women compared to
controls even years after delivery and that (2) 25-hydroxyvitamin D levels would be
related to insulin sensitivity and consequently with fasting insulin secretion. Thus in this
study we examined 25-hydroxyvitamin D levels in women with prior GDM compared to
a group of control women and interrogated the association between insulin resistance, β-
cell function and 25-hydroxyvitamin D levels among study participants.
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Materials and methods
Setting
We report the results of a case-control study (performed between 2008 and 2010) nested
within the cohort of all women delivered at Saint Margit Hospital, Budapest between
01/01/2005 and 31/12/2006. Saint Margit Hospital serves a mostly urbanized population
of 235 thousand people.
All pregnant women took part in a 2-step GDM screening program:
 First, a 75 gram 2-hour oral glucose tolerance test (OGTT) was performed at 16-18
weeks of gestation and evaluated using the WHO 1999 criteria (fasting glucose
≥7mmol/l and/or after 75g OGTT glucose level ≥ 7.8mmol/l).[31]  
 Those participants with normal glucose tolerance at the first test, subsequently had a
second OGTT at 24-28 weeks of gestation evaluated according to the same diagnostic
criteria.
All GDM women were referred to a dietitian and were given standardized dietary and
lifestyle advice. If fasting and 1-hour postprandial glucose targets (<5.3 mmol/l and 7.0
mmol/l, respectively) were not achieved, insulin therapy was initiated according to the
Recommendation of the Hungarian Diabetes Association with cut-offs similar to the
Canadian guideline.[32, 33]
Informed consent was obtained from all patients and the study was performed after
obtaining approval of Semmelweis University Regional and Institutional Committee of
Science and Research Ethics (Licence number: 124/2007) in accordance with the Helsinki
Declaration of the World Medical Association.
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Participants
During the study period altogether 3203 deliveries were recorded in the Saint Margit
hospital. Thirteen women were excluded because of known pregestational diabetes or
overt diabetes (based on a fasting glucose measurement at the first prenatal visit) and 45
women due to twin pregnancies. GDM was diagnosed in 193 cases (6.03%), a figure that
is somewhat lower than recently published GDM prevalence of 7.7 to 8.7% for the
Hungarian population.[34, 35]
All GDM women (n=193) and a randomly selected control group of women with normal
glucose tolerance during pregnancy (n=98) were invited for a follow-up investigation
3.2±0.6 years after delivery. All study participants were Caucasians. Of these potentially
eligible women 36/8 were excluded due to current pregnancy, breastfeeding, or known
diabetes. Of 157/90 eligible women, 87 (55.4%) with prior GDM and 45 (50.0%) controls
participated in the follow-up investigation. (Figure 1)
Study design
As the first step of the follow-up examination, questionnaires were sent to all potentially
eligible women. Based on information collected via these questionnaire women with
current pregnancy, lactation, or with known diabetes were excluded.
Eligible participants were invited to a detailed interview using a structured questionnaire
on maternal sociodemographic characteristics, lifestyle habits (smoking, caffeine and
alcohol consumption, physical activity, use of dietary supplements, nutrition), as well as
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medical and reproductive history and family history of diabetes. In addition a physical
examination including anthropometrics and blood pressure was performed.
Study participants underwent a 2-hour 75g oral glucose tolerance test. Fasting blood was
collected for other laboratory parameters.
Covariates and outcomes
Using questionnaire data age at follow-up was determined. Smoking status was coded as
never, ex-smoker or current smoker (≥5 cigarette/day). Physical activity was assessed by
the answers to questions on the frequency and duration of participation in moderate or
vigorous physical activity. Physical activity levels were classified as active (≥ 2.5 
hours/week of moderate or ≥1 hour/week of vigorous physical activity), inactive (≤ 1 
hour/week of moderate and ≤ 1 hour/week of vigorous physical activity), or moderately 
active (if not active or inactive).[36] Positive family history of diabetes was defined as
having a first degree relative with diabetes.
The use of vitamin D supplementation was defined as a report of regular intake of either
vitamin D tablets or multivitamins based on questionnaire data. Most multivitamin
compounds contain 400-600 IU of vitamin D in Hungary.
As 25-hydroxyvitamin D levels show a clear seasonal variation, we analysed date of
blood sampling divided into autumn/winter (October to March) and spring/summer (April
to September) as previously described.[37]
Regular sunbathing or sun bed use was defined as once a week outdoors (≥30 minutes 
midsummer midday sun exposure) or ≥20 minutes sun bed use per week. 
Abbreviations: BMI: Body Mass Index; CRP: C-reactive protein; γGT:  γ-glutamyl-
transferase; GDM: gestational diabetes mellitus; HDL: High-density lipoprotein; HOMA:
Homeostasis Model Assessment; HOMA2-B: HOMA insulin secretion; HOMA2-S: HOMA
insulin sensitivity; HPLC: high-pressure liquid chromatography; II: Insulinogenic index;
LDL: Low-density lipoprotein; OGTT: oral glucose tolerance test; 25(OH)D: 25-
hydroxyvitamin D
8
Body weight and height were measured in light clothing without shoes on a calibrated
digital scale. Weight was rounded to the nearest 0.1 kg, height to the nearest centimetre.
Waist circumference was measured at the height of the navel. BMI was calculated as
weight (kg) /(height (m) * height (m)).
Blood-pressure was measured three times using calibrated, digital blood-pressure meter
(OMRON M4-I, Omron Electronics Kft., Budapest, Hungary), on the upper arm, with
adequate sized (to upper arm circumference) cuff, after five minutes rest in the sitting
position. The average of the second and third measurements was used in the analysis.
Hypertension was defined as a blood pressure ≥ 140/90 mmHg or the regular use of 
antihypertensive medication.
All laboratory measurements were performed by the Central Laboratory of Semmelweis
University following standardized protocols.[38]] OGTTs were performed in the morning
(before 9:00 AM) after an overnight fast. Venous blood samples were drawn for
measurement of glucose and insulin levels at fasting and at 120 minutes after ingestion of
the glucose load. Serum glucose was measured using a glucose oxidase method on an AU
680 Beckman Chemistry System (Beckman Coulter Magyarország Kft. Budapest,
Hungary), insulin by electrochemiluminescence immunoassay (ECLIA) on a Cobas e601
automated system (Roche Diagnostics Magyarország Kft., Budaörs, Hungary).
Based on the glucose values during the 2-hour OGTT we defined glucose intolerance
(impaired fasting glucose, impaired glucose tolerance, or diabetes mellitus) as a fasting
glucose a ≥6.1 mmol/l and/or 2-h glucose ≥7.8 mmol/l.[31] 
To estimate insulin resistance we used the homeostasis model assessment (HOMA2
Calculator v.2.2, Diabetes Trials Unit, University of Oxford, Oxford, UK, can be accessed
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at https://www.dtu.ox.ac.uk/homacalculator/download.php).[39] Insulin sensitivity was
characterised by HOMA2-S, beta-cell function HOMA2-B. To characterise insulin
secretion we calculated the insulinogenic index: II= (insulin30 minutes-
insulinfasting)/(glucose30 minutes-glucosefasting) where insulin is entered in µIU/ml and blood
glucose in mmol/l.[40, 41] Fasting samples were used to determine HbA1c (high-
performance liquid chromatography, Bio-Rad Magyarország Kft., Budapest Hungary).
Serum lipids (cholesterol, High-density lipoprotein (HDL)-cholesterol, Low-density
lipoprotein (LDL)-cholesterol, triglyceride), gamma-glutamyl-transferase (γGT) were 
determined on an AU 680 Beckman Chemistry System (Beckman Coulter Magyarország
Kft., Budapest, Hungary).
The level of 25-hydroxyvitamin D was determined by chemiluminescent immunoassay
(CLIA) method with LIAISON 25-OH-vitamin D total assay (DiaSorin, Biomedica Kft.,
Budapest, Hungary). The 25(OH)D intra- and inter-assay coefficients of variation (CVs)
were 4.1–7.7% and 7.7–10.9%, respectively, at concentrations (24 and 8 ng/ml).
Functional sensitivity was defined at 2.2 ng/ml with a total allowable relative error of less
than 20%.[42]
Statistical analysis
All analyses were conducted using SPSS13.0 for Windows statistical software. Statistical
significance was inferred at a two-sided p value <0.05.
Continuous variables were presented in arithmetic mean (±SD), categorical variables as n
(percentage rate).
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To compare prior GDM and control women we used independent sample t-tests
(continuous variables) and Chi-squared or Fischer exact tests (categorical variables). The
distribution of continuous variables was tested for normality, and variables with a skewed
distribution were natural-log transformed.
To examine the association between insulin resistance (HOMA2-S) or beta-cell function
(II and HOMA2-B) and 25-hydroxyvitamin D levels we used two approaches.
First, we tested for univariate associations using linear regression of insulin
resistance/insulin secretion (outcomes) and 25-hydroxyvitamin D as a predictor. If a
significant association was found, we further adjusted for age and measures of obesity
(BMI or waist circumference).
Second, we looked for independent determinants of insulin resistance and insulin
secretion using 25-hydroxyvitamin D levels and those variables (listed in Table 1.)
univariately associated with these outcomes in a multiple logistic regression with stepwise
backward method. We selected one variable (with the strongest association with the
outcome) of those highly correlated with each other.
Results
Baseline characteristics
In total 87 patients with prior GDM and 45 controls with normal glucose tolerance during
pregnancy were examined. No significant difference in age, body mass index, waist
circumference, or the frequency of smokers was found between the prior GDM and
control groups. Prior GDM women were less physically active, had higher systolic and
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diastolic blood pressure values as well as an increased prevalence of hypertension
compared to controls. (Table 1)
Glucose intolerance was present in 24 women (28%) in the prior GDM group compared
to one woman (2.2%) in the control group (p<0.0001). Prior GDM women had
significantly higher HbA1c, fasting glucose, 120-minute post load glucose and insulin
levels, and insulinogenic index compared to controls (all p<0.05). No significant
between-group difference was found for estimated insulin sensitivity and insulin secretion
based on fasting measurements (HOMA2-S, HOMA2-B). There was no difference
between the two groups in other metabolic parameters examined, such as serum lipids and
γGT. (Table 1)
25-hydroxyvitamin D levels as well as frequency of 25(OH)D insufficiency were similar
in prior GDM and control women. Women with normal glucose tolerance or glucose
intolerance also had similar 25(OH) D values (24.6±10.2 vs. 28.1±12.6 ng/l). While the
time of blood draws and sunbed use were similarly prevalent among the prior GDM and
control groups, vitamin D supplementation was reported more often in the control group.
(Table 1)
Associations between insulin sensitivity and 25-hydroxyvitamin D levels and independent
determinants of insulin sensitivity
We found a univariately significant association between insulin sensitivity based on
fasting measurements (HOMA2-S) and 25-hydroxyvitamin D levels. Further, this
association remained statistically significant and did not attenuate substantially after
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further adjustments for age and measures of obesity (either BMI or waist circumference).
(Table 2A)
Using stepwise linear regression with backward elimination, the independent
determinants of HOMA IS were higher 25-hydroxyvitamin D levels, older age, lower
BMI, postload insulin, GT, and lower HbA1c levels. The full model explained 67% of
the variation in insulin sensitivity (r2=0.671). (Table 2B)
Associations between insulin secretion and 25-hydroxyvitamin D levels and independent
determinants of insulin secretion
There was a non-significant association between fasting insulin secretion (HOMA-2B)
and 25-hydroxyvitamin D levels (p=0.099) that was unaffected by adjustment for obesity
(either BMI or waist circumference). (Table 3A)
Using a similar stepwise linear regression with backward elimination, 25-hydroxyvitamin
D level was not among the independent determinants of HOMA 2B. Independent
determinants of HOMA-2B were younger age, higher BMI, γGT, and post load insulin. 
These variables explained 54% of the variation in insulin secretion (r2=0.541). (Table
3B).
Vitamin D levels were not related to insulinogenic index (β 0.058; p=0.55). 
Discussion
In the present study 25-hydroxyvitamin D levels were similar in prior GDM and control
women as well as between glucose intolerant and normal glucose tolerant women 3.2
years after delivery. We found a positive association between insulin sensitivity and 25-
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hydroxyvitamin D levels that remained significant after adjustment for age and measures
of obesity. There was a non-significant association between fasting insulin secretion and
25-hydroxyvitamin D levels. Furthermore, we found no association between the
insulinogenic index and 25-hydroxyvitamin D levels.
Our results in context
Increased prevalence of glucose intolerance and other abnormal glycaemic measures and
blood pressure levels are well described following a GDM pregnancy. Our current results
strengthen our previous findings and correspond to other literary observations [18, 43].
Maternal vitamin D deficiency has been linked to an elevated risk for GDM both cross-
sectionally and longitudinally.[19-21] Low 25-hydroxyvitamin D levels were
significantly associated with an elevated risk for GDM independently of maternal age,
family history of diabetes, and BMI in a nested case-control study from the US.[21]
However, some studies did not find an association between 25-hydroxyvitamin D levels
and the risk of GDM.[22-24]. Our study extends these observations, as we found no
difference in 25-hydroxyvitamin D levels between previous GDM and control women.
The interpretation of these findings is further complicated by the fact that 25-
hydroxyvitamin D levels are lower in pregnancy compared to non-pregnant levels.[44]
We could not find any associations between present glucose tolerance status and 25-
hydroxyvitamin D levels. It should be mentioned that our study included only a limited
number of diabetes cases and it would be absolutely necessary to raise this number prior
to drawing any conclusions about the prevalence of diabetes and the 25-hydroxyvitamin
D levels.[8, 15, 16] A recent prospective observational study of adults at high risk of
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diabetes from the US has found that higher plasma 25-hydroxyvitamin D levels (assessed
repeatedly during follow-up) were related to lower risk of diabetes.[45] On the other hand
low 25-hydroxyvitamin D status was independently associated with incident diabetes and
unfavourable longitudinal changes of continuous markers of glucose homeostasis in a
Danish population-based observational study.[46] A meta-analysis of prospective cohort
and case-control studies, based on 76,220 participants showed an significant inverse
association between 25-hydroxyvitamin D level and risk of incident type 2 diabetes.[47]
Much of the literature suggests that optimal 25-hydroxyvitamin D homeostasis is essential
for insulin action and secretion.[47] Using the gold standard hyperglycaemic clamp to
measure insulin sensitivity, an association between 25-hydroxyvitamin D levels and
insulin sensitivity was found even after controlling for BMI. There was also an inverse
association between first- and second-phase insulin response and serum 25(OH)D
concentrations although it became nonsignificant after adjustment for covariates.[9]
Using the other gold standard method (intravenous glucose tolerance test) Gulseth et al.
did not find any relationship between these parameters after adjustment for obesity.[2, 9]
In a large case-control study of nondiabetic adults with high diabetes risk and also in a
population sample the association between insulin sensitivity measured by HOMA and
25-hydroxyvitamin D levels was independent of BMI and other well-known diabetes risk
factors.[10, 11]
In gestational diabetes, 25-hydroxyvitamin D level was associated with HOMA insulin
sensitivity, with fasting glucose, post load glucose, HbA1c and with fasting insulin
level.[22, 23, 26-28] It is possible that due to a generally decreased insulin sensitivity
associated with pregnancy, glucose levels are more sensitive indicators of changes in
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insulin sensitivity related to 25-hydroxyvitamin D levels. In the present study the close
association between 25-hydroxyvitamin D level and HOMA insulin sensitivity was
independent of measures of obesity that corresponds closely to previous observations and
broadens them to the prior GDM women.
In the fasting state, there is a close relation between insulin sensitivity and insulin
secretion that is also taken into account when calculating HOMA values.[39] Our
observation that early insulin secretion (the insulinogenic index) was not related to 25-
hydroxyvitamin D levels, while it had a non-significant association with HOMA insulin
secretion, suggests that the connection of HOMA insulin secretion and 25-
hydroxyvitamin D levels indicates homeostatic changes in healthy people. Accordingly,
we suspect that 25-hydroxyvitamin D levels are primarily related to insulin sensitivity.
This hypothesis is supported by two experiments where vitamin D supplementation was
associated with improvements in insulin sensitivity among GDM women and in
nondiabetic adults with a high risk for diabetes.[12, 28]
Limitations and strengths
Several limitations of the present study should be mentioned. First, the measures of
insulin sensitivity and insulin secretion were based on fasting insulin and glucose values.
Although there is a close relation between HOMA-based insulin sensitivity and the
parameters based on the gold standard clamp method, HOMA insulin secretion values are
less validated. Second, because of the small sample size of our study, our results are
considered hypothesis generating. Third, the cross-sectional nature of our study makes it
impossible to investigate the temporal sequence prior to the abnormalities. Fourth, the
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method used for the measurement of 25(OH)D levels has known limitations, although the
quality control measures in our laboratory show acceptable performance. A strength of
our study is the fact that controls were selected from the same cohort of pregnant women
as the cases thus minimizing the potential bias related to control selection. We would like
to emphasise that to our knowledge, the connection between 25-hydroxyvitamin D levels
and insulin sensitivity after a GDM pregnancy has not yet been described in the literature.
Conclusions
In summary, although women with prior gestational diabetes have a higher incidence of
glucose intolerance at follow up, their vitamin-D levels are similar to those of control
women. On the other hand we found a negative association between HOMA insulin
sensitivity and 25-hydroxyvitamin D levels that was independent of age and BMI or waist
circumference. Intervention studies are required to elucidate whether the supplementation
of prior gestational diabetic women with vitamin D has any beneficial effects on incident
diabetes.
Acknowledgements: The present study was supported by the Hungarian Scientific Research
Fund (OTKA 68575/2007).
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1Table 1 – Baseline characteristics of study participants by prior GDM status.
prior GDM
(mean±SD) or
n (%)
control
(mean±SD) or
n (%)
p
n (number of cases) 87 45
Age (year ) 34.8±4.4 33.8±3.6 0.187
BMI† (kg/m²) 25.9±5.9 24.3±4.4 0.119
Waist circumference (cm) 84.4±13 81.3±9.4 0.183
Physical activity n (%) 0.025
active 12 (14.6%) 15 (34.9%)
moderately active 26 (31.7%) 12 (27.9%)
inactive 44 (53.7%) 16 (37.2%)
Smoker n (%) 16 (20.0%) 8 (19.0%) 0.900
Systolic blood pressure
(mm Hg)
122±17 116±14 0.031
Diastolic blood pressure
(mmHg)
78±11 72±11 0.004
Hypertension n (%) 22 (25.3%) 4 (8.9%) 0.0036
Glucose intolerance n (%) 24 (28%) 1 (2.2%) <0.0001
HbA1c (%) 5.6±0.4 5.4±0.3 0.009
Fasting glucose (mmol/l) 5.7±1.,1 5.2±0.4 <0.0001
120-minute glucose(mmol/l) 6.6±2.1 5.3 ±1.4 0.001
Fasting insulin (μIU/ml) 13.6±14.5 9.6±6.4 0.039 
120-minute insulin (μIU/ml) 69.2±61 37.3±27.3 <0.0001 
2HOMA2-S‡ 108±132 127±104 0.427
HOMA2-B § 99.6±42.6 97.9±41.4 0.842
Insulinogenic index
(mIU/mmol)
14±23 31±37 0.012
Cholesterol (mmol/l) 4.8±0.8 4.8±0.9 0.783
HDL cholesterol (mmol/l) 1.50±0.34 1.53±0.23 0.607
LDL cholesterol (mmol/l) 2.98±0,72 2.80±0.79 0.208
Triglyceride (mmol/l) 1.4±1.2 1.3±0.9 0.695
γGT● (IU/l) 19±11 18±13 0.824
25-hydroxivitamin D (ng/ml) 27.2±13.1 26.9±9.8 0.888
25-hydroxivitamin D
insufficiency (<20 ng/ml) n(%)
23 (28.4%) 8 (20.0%) 0.381
Blood draw in spring/summer
n (%)
28 (32.2%) 20 (44.4%) 0.185
Sunbathing, sun bed use n (%) 22 (26.5%) 13 (30.2%) 0.679
Use of Vitamin D supplement
n (%)
4 (4.6%) 12 (26.7%) <0.0001
†:Body mass index,‡: Homeostasis Model Assessment insulin sensitivity, §: Homeostasis
Model Assessment insulin secretion, ●: γ-glutamyl-transferase 
Table 2 –Association between (A) 25-hydroxyvitamin D levels and HOMA insulin sensitivity
(HOMA2-S) and (B) independent determinants of insulin sensitivity.
A
Independent variables β 95 %CI P 
25-hydroxyvitamin D (ng/ml) 0.017 0.001-0.034 0.04
+age, BMI† 0.016 0.002-0.030 0.031
+age, waist circumference 0.017 0.003-0.031 0.02
B
Independent variables β 95 % CI  P 
25-hydroxyvitamin D (ng/ml) 0.013 -0.0007-0.026 0.047
Age (year) 0.056 0.012-0.099 0.011
BMI† (kg/m²) -0.054 -0.018--0.089 0.004
120-minute insulin (μIU/ml) -0.203 -0,046- -0.35 0.013 
γGT● (IU/L) -0.019 -0.003- -0.034 0.024
HbA1c (%) -0.47 -1.00-0.582 0.085
†: Body Mass Index, ●: γ-glutamyl-transferase 
Multiple linear regression with log-transformed HOMA2-S as the outcome variable.
Independent determinants of HOMA2-S were selected using backward stepwise elimination
of non-significant terms. Other parameters available for the model were: C-reactive protein,
triglyceride, season of blood draw, and diastolic blood pressure (r2=0.671 for the model).
Table 3 – The association between (A) 25-hydroxyvitamin D levels and HOMA insulin
secretion (HOMA2-B) and (B) independent determinants of HOMA insulin secretion.
A
Output index HOMA2-B β 95% CI P 
25-hydroxyvitamin D (ng/ml) -0.009 0.002—0.019 0.099
+age, BMI† -0.008 0.002—0.018 0.106
+age, waist circumference -0.009 0.001—0.018 0.085
B
Output index HOMA2-B β 95% CI P 
Age (year) -0.032 -0,003--0,061 0,032
BMI† (kg/m²) 0.018 -0.005-0.042 0.018
γGT● (IU/L) 0.012 0.0002-0.024 0.044
120-minute insulin (μIU/ml) 0.158 0.05-0.266 0.005 
†: Body Mass Index, ●: γ-glutamyl-transferase 
Multiple linear regression with log-transformed HOMA2-B as outcome variable.
Independent determinants of HOMA2-B were selected using backward stepwise elimination
of non-significant terms. Other parameters available for the model were: triglyceride and
systolic blood pressure (r2=0.541 for the model).
All pregnant women
n=3203
Potentially eligible
n=3145
Excluded patients
• T1DM (n=3)
• T2DM (n=10)
• Twin pregnancies (n=45)
Gestational diabetes
n=193
Controls
n=2808
Eligible cases
n=157
Investigated GDM cases
n=87
Random selected controls
n=98
Investigated controls
n=45
3.2±0.6yrs of follow-up
Excluded women:
• current pregnancy,
• breastfeeding
• current diabetes
n=36/8
Excluded women
• withdrew consent
• missing data
n=76/45
Eligible controls
n=90
